Using a modified herpes virus to treat brain tumors
Author Information
Author(s): EA McKie, AR MacLean, AD Lewis, G Cruickshank, R Rampling, SC Barnett, PGE Kennedy, SM Brown
Primary Institution: Glasgow University
Hypothesis
Can the herpes simplex virus mutant 1716 effectively replicate in and kill primary human CNS tumors?
Conclusion
The HSV-1 mutant 1716 shows potential as a therapy for primary brain tumors by selectively replicating in tumor cells and causing cell death.
Supporting Evidence
- HSV-1 mutant 1716 can replicate in most glioma cell lines tested.
- 1716 causes cell death in glioma cells through selective replication.
- Normal human brain tissue was not available for comparative analysis.
Takeaway
Researchers are testing a special virus that can kill brain tumor cells without harming normal cells, which could help treat brain cancer.
Methodology
The study evaluated the replication of HSV-1 mutant 1716 in established human glioma cell lines and primary cell cultures from tumor biopsies.
Limitations
The study was limited by the inability to establish and grow sufficient normal human brain tissue for comparison.
Participant Demographics
Patients with anaplastic astrocytoma or glioblastoma multiforme.
Want to read the original?
Access the complete publication on the publisher's website